LGVN Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogenei…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value? Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […] | ||
 Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs. | ||
 Longeveron (LGVN) Q2 2026 Earnings Call Transcript ELPIS II trial data expected September 2026 as cash runway extends into Q4. | ||
 Longeveron Inc. Q2 2026 Earnings Call Summary Moby summary of Longeveron Inc.'s Q2 2026 earnings call | ||